Motor Cortex Lesion

2

Review clinical trials related to Motor Cortex Lesion. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors

The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraoperative direct electrical stimulation (DES) mapping and to resect as much tumor as possible without a resultant permanent neurological deficit. However, the subjective nature of current intraoperative hand motor assessments do not offer a comprehensive understanding of how hand strength and function may be impacted by resection. Additionally, there is a paucity of data to inform how altering DES parameters may effect motor mapping. Here, the investigators seek to demonstrate a feasible, standardized protocol to quantitatively assess hand strength and function and systematically assess several stimulation parameters to improve intraoperative measurements and better understand how cortical stimulation interacts with underlying neural function.

Participants needed: 20
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Medical College of WisconsinUpdated: May 11, 2026Locations: 1
Eligibility criteria

Age 18 - 75 [+7]

Presence of other malignancy not in remission [+7]

Status: Not yet recruiting

A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas

This study uses a cranial implant to deliver cortical stimulation that, when paired with physiotherapy, will remap the brain so that critical brain functions can be protected during brain tumor surgery. This pilot study will provide initial evidence for the safety and feasibility of such a protocol which will lead to future pivotal trials that could radically change eloquent area brain surgery. For patients with otherwise incompletely resectable brain tumors, this could mean a longer life expectancy and a better quality of life.

Participants needed: 3
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Medical College of WisconsinUpdated: Jan 12, 2026
Eligibility criteria

Age 18-65 years old [+7]

Presence of other malignancy not in remission [+14]